Get the Stockscreener App
9.19
0.43%
-0.04
After Hours:
9.08
-0.11
-1.20%
Benitec Biopharma Inc stock is traded at $9.19, with a volume of 5,880.
It is down -0.43% in the last 24 hours and down -0.59% over the past month.
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
See More
Previous Close:
$9.23
Open:
$9.24
24h Volume:
5,880
Relative Volume:
0.26
Market Cap:
$92.07M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-0.5424
EPS:
-16.9418
Net Cash Flow:
$-18.07M
1W Performance:
+3.49%
1M Performance:
-0.59%
6M Performance:
+75.05%
1Y Performance:
+204.13%
1-Day Range:
$8.92
$9.25
1-Week Range:
$8.5001
$9.33
52-Week Range:
$2.69
$10.88
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
Benitec Biopharma Inc Stock (BNTC) Latest News
JMP Securities Reiterates Market Outperform Rating for Benitec Biopharma (NASDAQ:BNTC) - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Benitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50 Day Moving Average of $8.85 - MarketBeat
Wall Street SWOT: Benitec Biopharma stock shows promise with OPMD treatment - Investing.com
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update - The Bakersfield Californian
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update - GlobeNewswire
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update - StockTitan
(BNTC) Trading Signals - Stock Traders Daily
51,216 Shares in Benitec Biopharma Inc. (NASDAQ:BNTC) Acquired by Simplify Asset Management Inc. - Defense World
Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update - Defense World
Short Interest in Benitec Biopharma Inc. (NASDAQ:BNTC) Decreases By 6.8% - MarketBeat
Benitec Biopharma Announces Late Breaking Oral Abstract - GlobeNewswire
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society - StockTitan
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar - GlobeNewswire
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar - StockTitan
Benitec Biopharma (NASDAQ:BNTC) Now Covered by Guggenheim - Defense World
Guggenheim Initiates Coverage of Benitec Biopharma (BNTC) with Buy Recommendation - Nasdaq
Benitec Biopharma (NASDAQ:BNTC) Receives New Coverage from Analysts at Guggenheim - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Stock Crosses Below 50 Day Moving Average of $8.99 - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below 50-Day Moving Average of $8.99 - Defense World
Benitec Biopharma approves equity plan amendment - Investing.com
Benitec Biopharma approves equity plan amendment - Investing.com India
Long Term Trading Analysis for (BNTC) - Stock Traders Daily
Benitec Biopharma Inc. (NASDAQ:BNTC) Sees Large Decline in Short Interest - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Shares Purchased by GAMMA Investing LLC - Defense World
Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market to Witness Astonishing Growth by 2031 | Benitec Biopharma Inc., Bioblast Pharma, BioMarin – TIMC - TIMC
Janus Henderson Group PLC Has $1.27 Million Stock Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC) - Defense World
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Above Fifty Day Moving Average of $8.25 - Defense World
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Above 50 Day Moving Average of $8.25 - MarketBeat
Janus Henderson Group PLC Has $1.27 Million Stock Holdings in Benitec Biopharma Inc. (NASDAQ:BNTC) - MarketBeat
(BNTC) Long Term Investment Analysis - Stock Traders Daily
Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Comprehensive Analysis by-Benitec Biopharma Inc., Bioblast Pharma – KnowCasino - KnowCasino
Piper Sandler Initiates Coverage of Benitec Biopharma (BNTC) with Overweight Recommendation - MSN
Leerink Partnrs Comments on Benitec Biopharma Inc.'s FY2024 Earnings (NASDAQ:BNTC) - MarketBeat
Benitec Biopharma Inc. to Post FY2024 Earnings of ($5.45) Per Share, Leerink Partnrs Forecasts (NASDAQ:BNTC) - Defense World
Benitec Biopharma (NASDAQ:BNTC) Rating Increased to Strong-Buy at Leerink Partnrs - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Rating Increased to Strong-Buy at Leerink Partnrs - Defense World
Benitec Biopharma (NASDAQ:BNTC) Research Coverage Started at SVB Leerink - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Now Covered by Analysts at SVB Leerink - Defense World
Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Above 50-Day Moving Average of $8.33 - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving Average of $8.33 - Defense World
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD... - Markets Insider
Benitec Biopharma Reports Promising Interim Study Results - TipRanks
Benitec's gene therapy shows sustained swallowing improvement in OPMD study - Investing.com
Benitec Biopharma (BNTC) Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First - StreetInsider.com
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phas - GlobeNewswire
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phas - Yahoo Finance
Short Interest in Benitec Biopharma Inc. (NASDAQ:BNTC) Expands By 871.6% - Defense World
Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update - MarketBeat
Top 5 NASDAQ Biotech Stocks of 2024 - Investing News Network
BNTCBenitec Biopharma Inc. Latest Stock News & Market Updates - StockTitan
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):